SCHEMBL301283

SCHEMBL301283

COc1ccccc1-n1c(=O)[nH]c2c(C(N)=O)nc(-c3ccncc3)nc21

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.81
GLA P06280 2/20 0.81
ALDH1A1 P00352 3/20 0.78
HPGD P15428 3/20 0.78
GAA P10253 2/20 0.78
SMN1; SMN2 Q16637 1/20 0.78
CSNK2A1 P68400 7/20 0.59
CSNK2A2 P19784 2/20 0.59
CSNK2B P67870 2/20 0.59
USP2 O75604 3/20 0.58
TSHR P16473 3/20 0.58
MAPK1 P28482 2/20 0.58
NPSR1 Q6W5P4 2/20 0.58
MAPT P10636 2/20 0.58
LMNA P02545 2/20 0.58
ESR1 P03372 1/20 0.58
TP53 P04637 1/20 0.58
HTT P42858 1/20 0.58
HSD17B10 Q99714 3/20 0.57
BRCA1 P38398 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL300825 0.91 KDM4E (0.82) KDM4EGLAALDH1A1HPGDGAA
SCHEMBL291560 0.90 KDM4E (0.81) KDM4EGLAALDH1A1HPGDGAA
SCHEMBL19254092 0.90 KDM4E (0.81) KDM4EGLAALDH1A1HPGDGAA
SCHEMBL300924 0.89 KDM4E (0.80) KDM4EGLAALDH1A1HPGDGAA
SCHEMBL296461 0.89 KDM4E (0.81) KDM4EGLAALDH1A1HPGDGAA
SCHEMBL300890 0.88 KDM4E (0.72) KDM4EGLAALDH1A1HPGDGAA
SCHEMBL301183 0.88 KDM4E (0.86) KDM4EGLAALDH1A1HPGDGAA
SCHEMBL297560 0.88 KDM4E (0.86) KDM4EGLAALDH1A1HPGDGAA
SCHEMBL300852 0.87 KDM4E (0.77) KDM4EGLAALDH1A1HPGDGAA
SCHEMBL300856 0.87 KDM4E (0.76) KDM4EGLAALDH1A1HPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2078018-B1 HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND USE THEREOF AS PROTEIN KINASE INHIBITORS SIGNAL PHARM LLC (US) 2012-03-14 EP claimed
CN-107976546-B Inhibition of phosphorylation of TOR kinase inhibitory Activity markers PRAS40, GSK 3-beta, or P70S6K1 西格诺药品有限公司 2020-10-27 CN disclosed
CN-110721186-A Treatment of prostate cancer with TOR kinase inhibitors 西格诺药品有限公司 2020-01-24 CN disclosed
CN-107157990-B Treatment of cancer with TOR kinase inhibitors 西格诺药品有限公司 2020-01-07 CN disclosed
CN-109846884-A With TOR kinase inhibitor for treating cancer 西格诺药品有限公司 2019-06-07 CN disclosed
CN-104271139-A Treatment of cancer with tor kinase inhibitors SIGNAL PHARM LLC 2015-01-07 CN disclosed
CN-104271138-A Treatment of cancer with tor kinase inhibitors SIGNAL PHARM LLC 2015-01-07 CN disclosed
CN-102821767-A IDENTIFICATION OF LKB1 MUTATION AS A PREDICTIVE BIOMARKER FOR SENSITIVITY TO TOR KINASE INHIBITORS SIGNAL PHARM LLC 2012-12-12 CN disclosed
EP-2078018-A1 HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND USE THEREOF AS PROTEIN KINASE INHIBITORS Signal Pharmaceuticals LLC (US) 2009-07-15 EP disclosed
WO-2008051494-A1 HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND USE THEREOF AS PROTEIN KINASE INHIBITORS SIGNAL PHARMACEUTICALS, LLC (US) 2008-05-02 WO disclosed